Boston Scientific (NYSE:BSX – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.29-2.34 for the period, compared to the consensus earnings per share estimate of $2.26. The company issued revenue guidance of +11-13% to ~$15.8-16.1 billion, compared to the consensus revenue estimate of $15.59 billion. […]
Boston Scientific (NYSE:BSX – Get Free Report) issued an update on its second quarter 2024 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.570-0.590 for the period, compared to the consensus EPS estimate of 0.560. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 […]
Boston Scientific (NYSE:BSX – Get Free Report) had its target price boosted by investment analysts at JPMorgan Chase & Co. from $72.00 to $82.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s price target suggests a […]
Boston Scientific (NYSE:BSX – Get Free Report) updated its second quarter 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.570-0.590 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $4.0 billion-$4.0 billion, compared to the consensus revenue estimate of $3.9 […]
PDS Planning Inc boosted its position in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 11.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,964 shares of the medical equipment provider’s stock after acquiring an additional 496 […]